Drug Resistance in Lung Cancer
Author Information
Author(s): J. Mattern, M. Bak, Jr., K.H. Hoever, M. Voim
Primary Institution: German Cancer Research Center
Hypothesis
How does drug resistance develop in a human epidermoid lung carcinoma xenograft line?
Conclusion
The study found that resistance to vincristine and actinomycin D developed rapidly, while resistance to cisplatin developed gradually.
Supporting Evidence
- Resistance to vincristine and actinomycin D was acquired by the second transplant generation.
- Growth delay for vincristine dropped from 7.2 to 2.8 days after treatment.
- Cisplatin resistance developed gradually and was incomplete after 8 treatments.
Takeaway
When treating lung cancer with certain drugs, the cancer can quickly learn to resist them, making the drugs less effective over time.
Methodology
The study involved treating a human lung cancer xenograft in nude mice with vincristine, actinomycin D, and cisplatin to observe the development of drug resistance.
Limitations
The study primarily focused on a single xenograft line, which may limit the generalizability of the findings.
Participant Demographics
Nude mice, NMRI (nu/nu) female, aged 6-10 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website